Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 124

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 124
---
 WO 2005/061018 includes patents Nos. US 8,007,774, US 8,858,925, US 9,120,872 and EP 1870115, which are detailed
in the table below.

While the first family of
patents form the “basic patent estate” covering the current products of the Company, diligent efforts have been made by the
Company to cover improvements and alternatives. Our “basic patent estate” has expiration date in December 2025. Although
the patents included in this “basic patent estate” are close to expiring, such patents only cover certain components in the
Company’s products. Our additional subsequently granted patents provide supplementary protection, as well as the latest pending
patent applications which cover subsequent improvements in the Company’s products and processes. Furthermore, regulatory approval,
when obtained, will yield certain types of non-patent exclusivities that can maintain the Company’s advantage even after expiration
of the earlier “basic patent estate”.

<div align='center'>75</div>

We also have additional subsequent
patents that we believe could prevent competitors from entering the market when patents directed to the specific conjugate molecules
expire. The additional patents are directed to manufacturing processes, formulations and other important technologies and serve to support
and extend patent protection beyond the earliest patents. While it is a fact that the earliest patent families are due to expire in the
next few years, we believe that the newest patent applications will provide protection to the updated products and processes for their
manufacture. The latest patent applications, some of which have matured to patents, are designed to protect various improvements to the
earliest filed patents, including improvements to the process of production, and ready to use formulations that may be administered from
pre-filled syringes and do not require in situ addition of activators prior to use.

The latest family of patent
applications is derived from WO 2017/103924 (granted in China, India and Israel and filed in other territories), and the objectives the
Company aims to achieve with these applications are to seek to obtain patent protection to cover improved compositions which are being
used or which may be used by the Company in the future. The improved compositions that the Company aims to protect with these applications
relate to otherhydrogels that are formed using Gelrin’s conjugates of polyethylene glycol and denatured fibrinogen. In particular,
the conjugates are generated using an improved process that avoids the use of